Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

27-Jul-2023 - Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced that Bristol Myers Squibb has made a $35 million equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a ...

Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation

Deal potential of $ 5 bn

11-May-2022 - Evotec SE announced that the Company has extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders. Based ...

Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type

Triggers US$ 9.0 m payment to Evotec

08-Oct-2021 - Evotec SE announced that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 m to Evotec. The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of ...

Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec

27-Apr-2021 - Evotec SE announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated this strategic drug discovery and development ...

Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb

Evotec receive a US$ 6 m payment

05-Jan-2021 - Evotec SE announced that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. Evotec and ...

Evotec and Bristol-Myers Squibb expand iPSC collaboration

08-Jan-2020 - Evotec SE announced that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines. Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to ...

Bristol-Myers Squibb Names Karen Vousden to Board of Directors

14-Sep-2017 - Bristol-Myers Squibb Company announced that its Board of Directors has elected Karen Vousden, Ph.D., to the Board, effective January 1, 2018. Dr. Vousden will serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden, 60, is currently group leader at the ...

Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics

11-Sep-2017 - Bristol-Myers Squibb Company announced that it has completed the previously announced planned acquisition of IFM Therapeutics. The transaction includes full rights to IFM’s preclinical STING (stimulator of interferon genes)and NLRP3 agonist programs focused on enhancing the innate immune ...

Bristol-Myers Squibb and QIAGEN collaborate

Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

07-Jun-2017 - Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer ...

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals

Gains full-rights to Cormorant’s HuMax-IL8 antibody program and lead asset HuMax-IL8 in Phase 1/2 Development

06-Jul-2016 - Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The ...